Immunovant

IMVTleader

Immunovant is developing FcRn inhibitors to reduce disease-causing IgG antibodies in autoimmune diseases, with batoclimab in multiple Phase III trials across 6+ indications.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($0M)

Data statis (memuat keuangan langsung…)

No product revenue (clinical stage) (100%)

Komposisi segmen dan pelanggan utama

Detail produk

Batoclimab (IMVT-1402)80%

Subcutaneous FcRn inhibitor reducing IgG antibodies — in Phase III for myasthenia gravis, CIDP, thyroid eye disease, and lupus nephritis.

IMVT-1402 (next-gen)20%

Next-generation FcRn inhibitor with enhanced half-life and selectivity vs. batoclimab for broader autoimmune pipeline.

Hubungan Rantai Pasok

Pesaing

Johnson & Johnson

Nipocalimab (FcRn inhibitor)

Dampak: significant

argenx

Vyvgart (efgartigimod)

Dampak: significant

Konteks makro dan pasar

헬스케어Berita sektor

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Katalis mendatang

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Immunovant.

Info Perusahaan

Kantor Pusat

New York, New York, USA

Didirikan

2018

Karyawan

260

Situs Web

immunovant.com

Gambaran umum sektor — 헬스케어

Berita sektor